Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5715753 | Annales de Pathologie | 2017 | 7 Pages |
Abstract
The assays for the assessment of the PD-L1Â status by immunohistochemistry are available in clinical studies in thoracic oncology to predict response to immunotherapies targeting the PD-1/PD-L1Â pathway. With the arrival of this new class of molecules in second line and very soon in first line of treatment for patients with advanced or metastatic non-small cell lung cancer, these tests will certainly be required in routine once these new drugs will be granted marketing authorization. The rapid introduction of these “companion” or “complementary” tests seems essential to select patients to benefit from these effective but also expensive and sometimes toxic therapies. Although challenged by some oncologists (as some patients not expressing PD-L1Â may sometimes respond to PD-1/PD-L1Â blockade), the anti-PD-L1Â immunohistochemically approach seems inevitable in 2017. This new activity developed in the pathology laboratories raises several questions: which anti-PD-L1Â clone should be used? On which device? What threshold of positivity should be considered? Should PD-L1Â expression be assessed on tumor cells as well as on the immune cells? What controls should be used? Comparative studies are underway or have been already implemented in order to answer some of these questions. This review addresses the different evaluation criteria for immunohistochemistry using the main anti-PD-L1Â antibodies used to date as well the recently published studies using these antibodies in thoracic oncology.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Pathology and Medical Technology
Authors
Paul Hofman, Marius Ilié, Sandra Lassalle, Elodie Long, Coraline Bence, Catherine Butori, Véronique Hofman,